1. Home
  2. GKOS vs WAL Comparison

GKOS vs WAL Comparison

Compare GKOS & WAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$102.57

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Logo Western Alliance Bancorporation (DE)

WAL

Western Alliance Bancorporation (DE)

HOLD

Current Price

$68.26

Market Cap

9.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
WAL
Founded
1998
1994
Country
United States
United States
Employees
N/A
3524
Industry
Medical/Dental Instruments
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
9.6B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
WAL
Price
$102.57
$68.26
Analyst Decision
Strong Buy
Buy
Analyst Count
14
16
Target Price
$133.07
$98.40
AVG Volume (30 Days)
652.0K
1.7M
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
2.47%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$507,442,000.00
N/A
Revenue This Year
$23.39
$20.16
Revenue Next Year
$27.46
$8.63
P/E Ratio
N/A
$10.88
Revenue Growth
32.33
N/A
52 Week Low
$73.16
$57.05
52 Week High
$130.23
$97.23

Technical Indicators

Market Signals
Indicator
GKOS
WAL
Relative Strength Index (RSI) 38.98 25.39
Support Level $81.54 N/A
Resistance Level $103.63 $79.68
Average True Range (ATR) 3.77 3.27
MACD -1.68 -1.39
Stochastic Oscillator 23.38 2.94

Price Performance

Historical Comparison
GKOS
WAL

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

Share on Social Networks: